

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACTAVIS, INC., ACTAVIS LABORATORIES FL, INC.,
ACTAVIS PHARMA, INC., AMNEAL PHARMACEUTICALS, LLC,
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC,
AUROBINDO PHARMA LTD., AUROBINDO PHARMA USA, INC.,
BRECKENRIDGE PHARMACEUTICAL, INC., VENNOOT
PHARMACEUTICALS, LLC, SANDOZ INC., SUN PHARMA GLOBAL FZE,
and SUN PHARMACEUTICAL INDUSTRIES, LTD.,
Petitioners

v.

RESEARCH CORPORATION TECHNOLOGIES, INC.,
Patent Owner

Case: IPR2014-01126
Patent RE 38,551

PETITIONERS' EXHIBIT LIST
(as of August 19, 2014)

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450
Submitted Electronically via the Patent Review Processing System

Pursuant to 37 C.F.R. § 42.63(e), Petitioners Actavis, Inc., Actavis Laboratories FL, Inc. (f/k/a Watson Laboratories, Inc. – Florida), Actavis Pharma, Inc. (f/k/a Watson Pharma, Inc.), Amneal Pharmaceuticals, LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Vennot Pharmaceuticals, LLC, Sandoz Inc., Sun Pharma Global FZE, and Sun Pharmaceutical Industries, Ltd. submit the following Exhibit List identifying the exhibit number and a brief description of each exhibit filed in connection with the above-captioned petition for *inter partes* review.

EXHIBITS

| Exhibit | Description |
|---------|--|
| 1001 | U.S. Patent No. RE 38,551 to Kohn (“’551 patent”) (reissue of U.S. Patent No. 5,773,475 (“’475 patent”)) |
| 1002 | Declaration of Clayton H. Heathcock, Ph.D. |
| 1003 | U.S. Patent No. 5,654,301 to Kohn and Watson (“’301 patent”) |
| 1004 | Jan. 28, 1998 Notice of Allowability (excerpt from prosecution history of ’475 patent) |
| 1005 | Philippe LeGall, <i>2-Substituted-2-acetamido-N-benzylacetamides. Synthesis, Spectroscopic and Anticonvulsant Properties</i> (Dec. 1987) (“LeGall thesis”) |
| 1006 | Apr. 10, 1998 Amendment Under 37 C.F.R. § 1.312 (excerpt from prosecution history of ’475 patent) |

| Exhibit | Description |
|---------|--|
| 1007 | Dec. 23, 2008 Application for Extension of Patent Term Under 35 U.S.C. § 156 (excerpt from prosecution history of '301 patent) |
| 1008 | U.S. Patent No. 5,378,729 to Kohn and Watson ("729 patent") |
| 1009 | Sergio Cortes et al., <i>Effect of Structural Modification of the Hydantoin Ring on Anticonvulsant Activity</i> , 28 J. Med. Chem. 601 (1985) ("Cortes") |
| 1010 | Harold Kohn et al., <i>Preparation and Anticonvulsant Activity of a Series of Functionalized α-Heteroatom-Substituted Amino Acids</i> , 34 J. Med. Chem. 2444 (1991) ("Kohn 1991") |
| 1011 | U.S. Food and Drug Administration, <i>Approved Drug Products With Therapeutic Equivalence Evaluations</i> 3-202, ADA 101 (34th ed. 2014) ("Orange Book") |
| 1012 | U.S. Provisional Patent Application No. 60/013,522 ("522 prov. app.") |
| 1013 | Apr. 14, 2014 Plaintiffs' Response to Defendants' Joint Set of Interrogatories (<i>UCB, Inc., et al. v. Accord Healthcare, Inc., et al.</i> , C.A. No. 13-1206-LPS (D. Del.)) |
| 1014 | Phillipe LeGall et al., <i>Synthesis of Functionalized Non-Natural Amino Acid Derivatives via Amidoalkylation Transformations</i> , 32 Int'l J. Peptide Protein Res. 279 (1988) |
| 1015 | R. L. M. Synge, <i>CCXXXIX. Experiments On Amino Acids. IV. The Methyl Ethers Of Some N-Acetyl-Hydroxyamino-Acids</i> , 33 Biochem. J. 1931 (1939) |
| 1016 | M. Jaeger et al., <i>Enzymatic Resolution of O-Methyl-N-acetyl-DL-serine. Amino Acids. XXXII.</i> , 28 Croat. Chem. Acta 5 (1956) |

| Exhibit | Description |
|---------|--|
| 1017 | Judith D. Conley & Harold Kohn, <i>Functionalized DL-Amino Acid Derivatives. Potent New Agents for the Treatment of Epilepsy</i> , 30 J. Med. Chem. 567 (1987) |
| 1018 | Judith D. Conley, <i>Functionalized Amino Acid Derivatives – Potent New Agents for the Treatment of Epilepsy: Synthesis, and Spectroscopic and Pharmacological Properties</i> (May 1986) |
| 1019 | Harold Kohn & Judith D. Conley, <i>New Antiepileptic Agents</i> , 24 Chemistry in Britain 231 (March 1988) |
| 1020 | European Patent Application No. 0 194 464 (“464 application”) |
| 1021 | Harold Kohn et al., <i>Marked Stereospecificity in a New Class of Anticonvulsants</i> , 457 Brain Res. 371 (1988) |
| 1022 | Harold Kohn et al., <i>Preparation and Anticonvulsant Activity of a Series of Functionalized α-Aromatic and α-Heteroaromatic Amino Acids</i> , 33 J. Med. Chem. 919 (1990) |
| 1023 | European Patent Application No. 0 263 506 (“506 application”) |
| 1024 | European Patent Application No. 0 400 440 (“440 application”) |
| 1025 | Harold Kohn et al., <i>Synthesis and Anticonvulsant Activities of α-Heterocyclic α-Acetamido-N-Benzylacetamide Derivatives</i> , 36 J. Med. Chem. 3350 (1993) |
| 1026 | Harold Kohn et al., <i>Anticonvulsant Properties of N-Substituted α,α-Diamino Acid Derivatives</i> , 83 J. Pharmaceutical Sci. 689 (May 1994) |
| 1027 | C.W. Thornber, <i>Isosterism and Molecular Modification in Drug Design</i> , 8 Chemical Soc’y Revs. 563 (1979) |

| Exhibit | Description |
|---------|---|
| | ("Thornber 1979") |
| 1028 | Wilson & Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, Ch. 2 (Delgado & Remers eds. 1991) ("W&G 1991") |
| 1029 | Richard B. Silverman, <i>The Organic Chemistry of Drug Design and Drug Action</i> , Ch. 2 (1992) ("Silverman 1992") |
| 1030 | Rosa Amoroso et al., <i>A New Route to the Synthesis of Amino Acids Through the Mercury Cyclization of Chiral Amidals</i> , 57 J. Org. Chem. 1082 (1992) |
| 1031 | S. Cerrini et al., <i>Serine-Containing 10-Membered Cyclodepsipeptides</i> , 41 Int'l J. Peptide Protein Res. 282 (1993) |
| 1032 | Svante Axelsson et al., <i>Versatile Synthesis of Stereospecifically Labelled D-Amino Acids via Labelled Aziridines</i> , J. Chem. Soc. Perkin Trans. 1 (1994) |
| 1033 | Oliver Keil et al., <i>New Hydantoinases from Thermophilic Microorganisms – Synthesis of Enantiomerically Pure D-Amino Acids</i> , 6 Tetrahedron: Asymmetry 1257 (1995) |
| 1034 | Patrick Bardel et al., <i>Synthesis and Anticonvulsant Activities of α-Acetamido-N-Benzylacetamide Derivatives Containing an Electron-Deficient α-Heteroaromatic Substituent</i> , 37 J. Med. Chem. 4567 (1994) |
| 1035 | FDA, <i>Guideline for Industry: Dose-Response Information to Support Drug Registration</i> (Nov. 1994) |
| 1036 | R. Schmidt, <i>Dose-Finding Studies in Clinical Drug Development</i> , 34 Eur. J. Clin. Pharmacol. 15-19 (1988) |
| 1037 | Declaration of James F. Hurst in Support of Motion for Pro Hac Vice Admission |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.